BioSpace News Archive

Vera Therapeutics, Inc., a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host a business update call at 8:00 a.m. ET on March 24, 2022.

“Throughout 2021, we continued to make steady progress in developing our comprehensive, next-generation iPSC-based cell therapy platform, executed on our powerful discovery engine, and we believe we are positioned to transition to a clinical stage company in 2022.

Zepp Health Corporation (“Zepp” or the “Company”) (NYSE: ZEPP) today reported revenue of RMB1.7 billion ( US$260.7 million ); GAAP diluted net income per share of RMB0.14 (US$0.02) ; and GAAP diluted net income per ADS of RMB0.55 (US$0.09) for the fourth quarter ended December 31, 2021.

Labcorp is the first U.S. commercial laboratory to offer a new test developed by Immundiagnostik, Inc. to help individuals detect and quantify unintentional gluten consumption.

Brain Scientific announces the appointments of Felicia Maher as VP of Sales for Medical Products and Todd Bertrand as VP of Sales for Motion Products.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2021 on Thursday, March 24.

Oyster Point Pharma, Inc. today announced that William J. Link, Ph.D., is retiring from Oyster Point’s Board of Directors, effective as of March 17, 2022.

Impel NeuroPharma announced two separate transactions with funds managed by Oaktree Capital Management, L.P. totaling $100 million in gross funding.

RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients.

Mainz Biomed N.V. announced partnerships with Sentinel Diagnostics and Alcedis GmbH to support ColoFuture, its clinical study evaluating the potential to integrate a portfolio of novel mRNA biomarkers into ColoAlert, the Company’s highly efficacious, and easy-to-use detection test for colorectal cancer.